Emergo Therapeutics
NC - DurhamBiotechnology
Focus: Emergo Therapeutics is a Durham-based biotech founded in 2016 focused on inflammation modification in immunology, currently advancing a clinical-stage pipeline centered on Norketotifen across multiple indications.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Open Jobs
6
Should You Work at Emergo Therapeutics?
AI assessmentBest suited for early-career scientists or data professionals seeking exposure to clinical-stage immunology in a lean, pre-revenue environment with meaningful execution risk.
Why Work Here
- Opportunity to join early-stage immunology company with multiple Phase 2 programs in high-prevalence indications (allergic rhinitis, influenza)
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Left Ventricular Assist System
Advanced Refractory Left Ventricular Heart FailureClinical Trials (1)
NCT02170363HeartMate 3™ CE Mark Clinical Investigation Plan
N/AHelp build intelligence for Emergo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.